Every 8-K that SYRA HEALTH CORP A (SYRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRA filings page.
Syra Health Corp. reported a strong second quarter ended June 30, 2026, with revenue of $2.4 million, up 23% from $1.9 million a year earlier. The company achieved net income of $250,242, compared with a net loss of $63,596, and earnings per share improved to $0.02 from a loss of $0.01.
Gross margin expanded to a record 44.5% from 38.7%, and Q2 EBITDA turned positive to $253,200 from a loss of $53,760. For the first six months of 2026, net income was $491,221 and operating cash flow was $643,183. Cash stood at $2.1 million with no long-term debt. The company renewed key public health and workforce contracts, extended an Indiana FSSA agreement through October 2028, and is pursuing CMS ACCESS Model approval it expects to provide long-term revenue, while targeting full-year 2026 profitability.
Syra Health Corp. held its Annual Meeting of Stockholders on July 23, 2026, with 13,664,105 shares of common stock represented, including 350,000 Class B shares carrying 16.5 votes per share, constituting a quorum.
Stockholders elected all five director nominees to serve until the 2027 annual meeting. They also ratified M&K CPAs, PLLC as independent registered public accounting firm for the fiscal year ended December 31, 2026, with 12,133,305 votes in favor. In addition, stockholders approved an amendment to the Company's 2022 Omnibus Equity Incentive Plan, increasing the number of Class A shares available for issuance to 4,100,000, with 8,548,265 votes for and 2,691,142 against.
Syra Health Corp. reported its first profitable quarter in Q1 2026. Net income was $240,979, compared with a net loss of $(472,265) a year earlier. Revenue grew 22% to $2.27 million, driven by population health solutions, which rose 46% to $1.8 million.
Gross margin expanded to 42.7% from 31.7% as the company shifted toward higher-margin offerings and improved operating leverage. Operating expenses declined across salaries, professional services, SG&A, and R&D, supporting adjusted EBITDA of $244,495 versus a loss in 2025. Cash and cash equivalents increased to $2.9 million with strong operating cash flow.
Syra Health Corp. reported FY2025 results showing a much smaller loss and stronger margins despite lower revenue. Net revenues were $7.2 million versus $8.0 million in FY2024, mainly due to reduced federal funding to state and county customers.
Population Health revenue grew 157% to $5.3 million, becoming a key growth engine. Net loss narrowed to ($896,333) from ($3,759,238), and earnings per share improved to ($0.08) from ($0.50). Gross margin increased to 34.4% from 20.7% as cost of services fell.
Total operating expenses declined to $3.4 million from $5.4 million, and adjusted EBITDA improved to ($863K) from ($3.7 million). Cash was $1.6 million with no long-term debt as of December 31, 2025, while management highlighted a strategic shift toward integrated healthcare solutions and reiterated a goal of reaching profitability by year-end 2026.
Syra Health Corp. appointed Gregory R. Alexander as Chief Executive Officer under an employment agreement effective January 5, 2026.
The agreement provides a $251,000 annual base salary, a target bonus equal to 30% of base pay, 110,537 restricted stock units, options to purchase 257,920 shares of Class B common stock and 368,458 performance stock units, with specified vesting dates and performance conditions. It also includes non-competition and non-solicitation covenants, cash severance of six months’ base salary plus bonus and benefits in certain terminations without cause or for good reason, and accelerated vesting of unvested equity if his employment ends in connection with defined change of control scenarios.
Syra Health Corp. has amended its Amended and Restated Certificate of Incorporation to change how its Class B common stock converts. Stockholders approved these changes on November 14, 2025, after a recommendation from the Board of Directors. The amendment deletes a provision that caused automatic conversion of Class B shares upon the death of a Class B stockholder. It also expands who can receive transfers of Class B shares, allowing transfers to immediate family members, heirs, successors and assigns without triggering conversion of those Class B shares. The amendment was filed in Delaware on November 18, 2025 and became effective upon filing.
Syra Health Corp. reported the results of its Annual Meeting of Stockholders. A total of 15,848,410 shares were represented, including 600,000 shares of Class B common stock with 16.5 votes per share.
All five director nominees were elected. Stockholders ratified M&K CPAs, PLLC as independent auditor for the year ended December 31, 2025 with 14,955,596 For, 369,733 Against, and 523,081 Abstain.
Two charter amendments affecting Class B voting structure were approved: (1) deletion of the provision that automatically converts Class B common stock upon the death of a Class B stockholder; and (2) expansion of permitted transfers so that immediate family members, heirs, successors, and assigns may receive Class B shares without those shares converting.
Syra Health Corp. filed an 8-K announcing it furnished its third-quarter 2025 results press release. The company reported that a press release covering the quarter ended September 30, 2025 is attached as Exhibit 99.1.
The company stated the information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into other filings unless specifically referenced. The exhibit also includes forward-looking statements subject to cautionary language.